Horizon Discovery combines deep scientific experience in translational research with a precision gene-editing platform incorporating rAAV, CRISPR and ZFN technologies. Horizon supplies genetically-defined cell lines, in vivo models, custom cell line generation, molecular reference standards, and contract research services to over 1,000 academic, clinical and biopharmaceutical organizations.
|Address:||Building 7100, IQ Cambridge, Waterbeach|
|Membership type:||Founder Member|
Horizon powers genomic research and translational medicine from sequence to treatment.
Horizon Discovery is a UK Biotechnology company founded in 2007, and built upon a 20 year heritage in oncology research, translational medicine and gene-editing. The company’s unique history and experience has culminated in a precision gene-editing platform that incorporates rAAV, CRISPR and ZFN technologies. Horizon is the only company that has access to such a broad range of tools, allowing any genome modification challenge to be addressed.
In total, Horizon offers over 16,000 products, almost all of which are based on the application of gene editing to generate cell lines that accurately model the disease-causing mutations found in genetically based diseases. These ‘patients-in-a-test-tube’ are being used by customers to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, which may lead to the successful prediction of which patient sub-groups will respond to currently available and future drug treatments.
In addition, Horizon provides custom cell line and in vivo model generation services for research and bioproduction applications, quantitative molecular reference standards, in vivo disease models, and contract research and custom screening services.
Horizon aspires to provide science-driven research solutions that lead to advancement in the understanding of the genetic basis of disease and better healthcare outcomes for patients, ultimately providing the tools to identify the ‘right drugs’ for the ‘right patients’ based upon the unique genetic mutations that define their disease.
Panel of ‘off-the-shelf’ isogenic cell-lines that model common genes that occur in human cancer, plus provide their perfectly matched normal genetic backgrounds as a reference.
Using its precision gene-editing platform that incorporates rAAV, CRISPR and ZFN technologies, Horizon is able to alter any endogenous gene sequence of a human or mammalian cell line quickly, reliably and without introducing unwanted and confounding genotypes and/or phenotypes.
Molecular & Cellular Biology
In vitro Functional Assays & Pharmacological Validation
In vivo Functional Validation
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today notes its complete RNA reference standards product range have been endorsed by Thermo Fisher Scientific for use in its Ion Ampliseq and Oncomine fusion assays for cancer research.
15 June 2017Read in full
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announces progress of its gene and cell therapy platform for contract service and therapeutic applications. The new offering will make use of Horizon’s extensive suite of gene editing technologies, including CRISPR and its proprietary rAAV and Transposon technologies, to edit pluripotent stem cells (iPSC) and primary human lymphocytes.
14 June 2017Read in full
ATUM (formerly DNA2.0, Inc.) and Horizon Discovery, the world leader in the application of gene editing technologies, today announced they have signed a cross-licence agreement for Horizon’s CHO SOURCE platform and ATUM’s vector technology to speed development of highly productive stable cell lines for drug development.
1 June 2017Read in full
Horizon Discovery Group plc, a world leader in the application of gene editing technologies, announces its preliminary results for the year ended 31 December 2016.
30 May 2017Read in full
Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies, today provides an update on the performance of its Immuno-Oncology platform, which combined represents over £1.5 million in current and ongoing product sales and contract research projects in FY17 to date, with a very strong order book in place for the remainder of the year.
9 May 2017Read in full
Horizon Discovery Group plc, the world-leader in the application of gene editing technologies, today announces it has entered into an agreement with a global leader in the development and provision of innovative molecular diagnostic testing solutions (the Client).
14 March 2017Read in full
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, including the provision of bioproduction cell lines, today announced it has entered into a research and development collaboration, and licence agreement with AmplyCell SA, to evaluate the impact of AmplyCell’s BOOST cell line optimisation technology on Horizon’s parental GS (glutamine synthetase) null CHO K1 cell line.
8 March 2017Read in full
Horizon Discovery Group plc, the world leader in the application of gene editing technologies including molecular reference standards, today announces the launch of its first HDx™ cfDNA (cell-free DNA) Reference Standard in Synthetic Plasma.
20 February 2017Read in full
Horizon Discovery today announces the signing of a Master Services Agreement (MSA) with a top three global pharmaceutical company extending support for their drug discovery and development efforts to Horizon’s full suite of services.
14 February 2017Read in full
Horizon Discovery Group plc, the world leader in the application of gene editing technologies, today announces a trading update ahead of its full year results for the 12 months ended 31 December 2016. The Group intends to announce its preliminary full year 2016 results in May 2017.
24 January 2017Read in full
17 Oct 2017 - 18 Oct 2017Smock Alley Theatre, Dublin, Ireland
CRISPR gene editing - Drug discovery tool or therapeutic revolution? This unique meeting will bring leaders in the field together with a wide academic and commercial audience. A substantial proportion of the oral programme will be given over to talks selected from submitted abstracts. Join us to learn about the next wave of CRISPR innovation.